Peptide Therapeutics: A Literature Course

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing below is a protocol, a recommendation, or a suggestion that any reader use any compound. Each module summarises what the cited peer-reviewed literature reported and ends with the limits of that evidence.

Module 1: What Peptide Therapeutics Are and How They Have Been Studied

Definition and class

Peptide therapeutics are drug molecules composed of amino acids linked by amide bonds, occupying the chemical space between traditional small molecules and large protein biologics. A 2015 review in Drug Discovery Today described peptide therapeutics as a distinct and growing drug class and surveyed the approved agents and the pipeline of candidates in clinical development at that time (PMID 25450771). A separate 2018 historical review in Bioorganic & Medicinal Chemistry traced therapeutic peptides from early insulin-era products through to modern development trends, describing how the field grew from extracted natural hormones into rationally engineered molecules (PMID 28720325).

Origins of the molecules

The literature groups the starting points into a few recurring categories. A 2018 review described a "peptide chemistry toolbox" used to transform natural peptides — hormones, venom components and other endogenous ligands — into peptide therapeutics with drug-like properties, covering backbone modification, cyclisation, unnatural amino acids and conjugation (PMID 29395804). A 2013 ChemMedChem review addressed polycyclic peptide therapeutics specifically, describing peptides constrained into multiple rings to improve target binding and stability relative to linear sequences (PMID 23355488).

Forms described in the literature

• Linear peptides — the simplest form, discussed across the general reviews (PMID 32414106).
• Cyclic and polycyclic peptides — constrained architectures reviewed as a route to improved stability and affinity (PMID 23355488).
• Peptide–drug conjugates — a 2024 Journal of Medicinal Chemistry review described conjugates in which a peptide acts as a targeting or delivery element attached to a payload, presented as an emerging direction for the next generation of peptide therapeutics (PMID 38277480).
• Multi-agonist peptides — a 2026 Chemistry review described modular assembly strategies for building single peptide molecules that engage more than one receptor (PMID 42315994).
• Oral formulations — a 2020 Nature Reviews Drug Discovery review covered advances in oral peptide therapeutics, including permeation enhancers and formulation strategies (PMID 31848464).

Limits of the evidence in Module 1

The sources cited here are reviews rather than primary experiments, so the definitions and categories they offer reflect editorial framing and the literature available at the time of writing. Reviews from 2013 through 2026 use overlapping but not identical residue-length cut-offs for what counts as a "peptide", and none of the cited works establishes a single regulatory or chemical boundary between peptides, peptidomimetics and small proteins.

Module 2: Mechanism as Described in the Literature

Target engagement

Reviews of the class consistently describe peptides as ligands that reproduce or block natural protein–protein and hormone–receptor interactions. The 2015 status review described peptide therapeutics as agents that exploit high target affinity and selectivity, a property attributed to their larger interaction surface compared with small molecules (PMID 25450771). The 2020 Molecules review, framed as "Peptide Therapeutics 2.0", discussed how contemporary design approaches extended peptides beyond classical receptor agonism toward previously intractable intracellular and protein–protein interaction targets (PMID 32414106).

Chemical strategies that shape mechanism

The mechanistic behaviour of a peptide drug is, in the literature's account, largely a function of the chemistry applied to it. The 2018 toolbox review described stapling, cyclisation, backbone N-methylation, incorporation of D-amino acids and lipidation as methods used to convert a fragile natural peptide into a molecule that retains target engagement in vivo (PMID 29395804). Polycyclic scaffolds were described as a way to pre-organise the binding conformation and resist proteolysis (PMID 23355488).

Conditional and targeted mechanisms

Some designs are described as conditionally active. A 2022 ACS Nano paper described conditional antimicrobial peptide therapeutics, in which antimicrobial activity was intended to be unmasked only under defined local conditions rather than acting constitutively (PMID 35980829). Peptide–drug conjugates were described as separating the targeting function (the peptide) from the pharmacological payload, with linker chemistry governing release (PMID 38277480).

Limits of the evidence in Module 2

Mechanistic descriptions in reviews are generalisations across many different molecules. A mechanism demonstrated for one peptide against one target does not transfer to other peptides, and the cited reviews did not test mechanism directly. Several strategies described — conditional activation, modular multi-agonism — were reported at preclinical or conceptual stages rather than as established clinical mechanisms.

Module 3: Reported Outcomes by Study

What the reviews reported

Across these sources, no single endpoint or effect size is common to the class. Oral peptide work reported formulation feasibility as the primary endpoint rather than clinical benefit (PMID 31848464), while disease-area reviews in neurodegeneration (PMID 24533803) and genetic disorders (PMID 39419376) described candidates at investigational stages.

Limits of the evidence in Module 3

None of the verified sources reported a specific dose, dosing interval or quantified effect size that can be reproduced here, so no dose figures appear on this page. "Peptide therapeutics" is a chemical class, not a single intervention; outcomes reported for one approved peptide say nothing about another. Narrative reviews do not use systematic search or risk-of-bias methods, and several cited reviews describe preclinical work only.

Module 4: Peptide Therapeutics Side Effects: What Studies Report

The verified literature discusses tolerability at the level of the class and its delivery strategies rather than as pooled adverse-event tables. Two themes recur.

Immunogenicity and off-target activity

The 2015 status review discussed immunogenicity among the liabilities that have historically constrained peptide drug development alongside poor stability and short duration of action (PMID 25450771). The 2018 historical review likewise reported that development trends in therapeutic peptides have been shaped by the need to manage stability and tolerability limitations of natural sequences (PMID 28720325). The conditional antimicrobial peptide work was framed around limiting non-selective membrane activity, with researchers reporting that constitutively active antimicrobial peptides carry host-cell toxicity concerns that conditional activation was designed to address (PMID 35980829).

Delivery-related tolerability

Oral delivery introduces its own tolerability questions. The 2020 oral peptide review reported that permeation enhancers used to increase gastrointestinal absorption raise questions about local epithelial effects and the selectivity of absorption enhancement (PMID 31848464). The 2025 narrative review of oral peptides in immune-mediated inflammatory disease similarly discussed safety and tolerability considerations alongside efficacy signals for this route (PMID 40439953). For conjugates, the 2024 review noted that payload chemistry and linker stability determine the toxicity profile of a peptide–drug conjugate as much as the peptide itself (PMID 38277480).

Limits of the evidence in Module 4

None of the cited papers reported incidence rates, severity grading or comparative adverse-event frequencies for peptide therapeutics as a group. Class-level discussion of immunogenicity or local tolerability cannot be translated into an expected adverse-event profile for any individual molecule. Adverse events for approved peptide products appear in their own product labelling and trial reports, which are outside the verified source list used here.

Module 5: Pharmacokinetics Where Data Exist

The core pharmacokinetic problem

The literature is consistent that unmodified peptides are poor drugs pharmacokinetically. The 2015 review described short plasma half-life and rapid proteolytic degradation as defining constraints on the class and a central focus of medicinal chemistry effort (PMID 25450771). The 2018 toolbox review catalogued the chemical responses — cyclisation, D-amino acid substitution, N-methylation, lipidation and conjugation — reported as means of extending exposure and resisting enzymatic cleavage (PMID 29395804).

Oral bioavailability

Oral absorption is the most extensively reviewed pharmacokinetic obstacle. The 2020 Nature Reviews Drug Discovery review reported that gastrointestinal proteolysis and poor epithelial permeability historically restricted peptides to parenteral routes, and described the formulation technologies developed in response (PMID 31848464). The 2025 review extended this to immune-mediated inflammatory disease, reporting oral peptides as a route under active clinical development (PMID 40439953).

Distribution to restricted compartments

The 2014 neurodegeneration review discussed blood–brain barrier penetration as a limiting factor for peptide therapeutics aimed at central nervous system targets (PMID 24533803). Conjugation has been described as one distribution strategy, with the 2024 review reporting that peptide carriers can direct payloads toward specific receptors or tissues (PMID 38277480).

Limits of the evidence in Module 5

No half-life values, clearance rates, bioavailability percentages or volume-of-distribution figures are stated here because the verified sources are class-level reviews that do not supply reproducible parameters for a named molecule. Pharmacokinetics differ by orders of magnitude across peptide drugs depending on sequence, modification and formulation, so class-level statements have no predictive value for individual agents.

Module 6: Regulatory Status

Approved products exist within the class

Peptides are an established regulated drug category, not an exclusively experimental one. The 2015 status review described a body of approved peptide drugs on the market alongside a clinical pipeline (PMID 25450771), and the 2018 historical review traced the regulatory-era arc of therapeutic peptides from early approvals to contemporary development (PMID 28720325). Approval always attaches to a specific product, sequence, formulation, indication and manufacturer — never to "peptides" as a category.

Research-use-only material

Separately from approved medicines, many peptide sequences are distributed as research chemicals labelled "research use only" (RUO). RUO labelling indicates that a material has not been evaluated or authorised by a regulator for administration to humans and is intended for laboratory work. An RUO peptide sharing a sequence with an investigational or approved drug does not inherit that drug's regulatory status, manufacturing controls or safety evaluation.

Compounding

In the United States, compounding pharmacies may prepare certain drug products under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounded preparations are not FDA-approved products and are not reviewed for safety, efficacy or manufacturing quality in the way approved drugs are. The eligibility of individual peptide substances for compounding has been the subject of ongoing regulatory review. This section states regulatory facts for educational context and is not legal advice.

Limits of the evidence in Module 6

The verified scientific reviews describe the development landscape, not current regulatory determinations. Approval status, scheduling and compounding eligibility change over time and vary by jurisdiction; nothing in the cited literature reflects the status of any product on any particular date.

What the Studies Did Not Test

• Doses for individuals. None of the verified sources reported a dose, frequency or duration that could be applied to any person; no dosing information appears anywhere on this page.
• Non-clinical use. The cited reviews examined peptides as investigational or approved medicines (PMID 32414106), not as wellness, performance or cosmetic products used outside medical supervision.
• Long-term safety of the class. No cited paper reported multi-year safety follow-up across peptide therapeutics.
• Head-to-head comparisons. The reviews did not compare peptide therapeutics against small molecules or antibodies in controlled trials with shared endpoints.
• Combinations. Although modular multi-agonist design was described as a chemical strategy (PMID 42315994), the sources did not evaluate ad hoc combinations of separate peptide products.
• Unregulated material. No cited study assessed the identity, purity or content of peptides obtained outside regulated pharmaceutical supply chains.

This page summarises published literature for educational purposes only and is not medical advice; readers with health questions should consult a licensed physician.

References

• Peptide therapeutics: current status and future directions (Drug Discovery Today, 2015)
• Advances in oral peptide therapeutics (Nature Reviews Drug Discovery, 2020)
• Peptide Therapeutics 2.0 (Molecules, 2020)
• Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics (Bioorganic & Medicinal Chemistry, 2018)
• Conditional Antimicrobial Peptide Therapeutics (ACS Nano, 2022)
• Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics (Journal of Medicinal Chemistry, 2024)
• Therapeutic peptides: Historical perspectives, current development trends, and future directions (Bioorganic & Medicinal Chemistry, 2018)
• Polycyclic peptide therapeutics (ChemMedChem, 2013)
• Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review (Advances in Therapy, 2025)
• Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics (Chemistry, 2026)
• Peptide-based therapeutics targeting genetic disorders (Drug Discovery Today, 2024)
• Peptide therapeutics in neurodegenerative disorders (Current Medicinal Chemistry, 2014)